KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Compare Efficacy, Safety, and Tolerability of KN046 Combined With Lenvatinib Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer After Failure of Anti-PD-(L)1 Agent

This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy. Subjects should have documented progressive disease during prior treatment with first- or second-line PD-(L)1 and platinum-containing dual-agent chemotherapy.Subjects will be randomized to two treatment groups in a 1:1 ratio.

Treatment Group: KN046 5mg/kg Q3W + lenvatinib recommended for phase III dose (RP3D) every day.

Control group: Docetaxel 75mg/m2 Q3W .

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Shanghai
      • Shanghai, Shanghai, China
        • Shanghai Pulmonary Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  • Has a histologically confirmed or cytologically confirmed diagnosis of advanced NSCLC;
  • Non-squamous non-small cell lung cancer, no EGFR mutation or ALK rearrangement or ROS1 fusion, no known RET fusion or MET14 exon jump mutation; Squamous non-small cell lung cancer with no known EGFR mutation or ALK rearrangement or ROS1 fusion /RET fusion /MET14 exon jump mutation;
  • Has received prior systemic treatment with first- or second-line PD-(L)1 and platinum-containing dual-agent chemotherapy for their advanced NSCLC;
  • Has measurable disease;
  • Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;
  • Has adequate organ function;
  • Has a life expectancy of at least 3 months;
  • If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment;
  • If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.

Exclusion Criteria:

  • Untreated active central nervous system metastasis or leptomeningeal metastasis;
  • Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;
  • Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and/or if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment;
  • Curative radiation within 3 months of the first dose of trial treatment;
  • Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to < 10 mg prednisone daily, inhaled steroids and topical use of steroids);
  • Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines;
  • Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;
  • History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent;
  • Previous malignant disease;
  • History of uncontrolled intercurrent illness;
  • Prior therapy with any antibody/drug targeting T cell coregulatory proteins;
  • Has received treatment with lenvatinib or docetaxel or VEGFR-TKI;
  • Known severe hypersensitivity reactions to antibody drug;
  • Is pregnant or breastfeeding;
  • Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Docetaxel
Active Comparator: docetaxel 75 mg/m² every 3 weeks until progressive disease or unacceptable toxicity.
Docetaxel is 75 milligram per Square meter, every 3 weeks.
Experimental: Cohort 1: KN046 plus Lenvatinib RP3D.
Experimental arm: Cohort 1: KN046 5mg/kg every 3 weeks + lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
Lenvatinib is RP3D milligram per day, every day.
KN046 is 5 milligram per kilogram, every 3 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OS
Time Frame: up to 2 years
Overall survival (OS) was defined as the time from randomization to death due to any cause (phase 3).
up to 2 years
PFS
Time Frame: up to 2 years
Progression-free survival (PFS) was defined as the time from randomization grouping to the first documented disease progression or death from any cause as evaluated by the investigator according to RECIST 1.1 criteria (phase 3).
up to 2 years
DLT
Time Frame: 28 days or 21 days
Dose limit toxicity (phase 2)
28 days or 21 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ORR
Time Frame: up to 2 years
Objective response rate (ORR) based on the RECIST 1.1 by principal investigator
up to 2 years
DCR
Time Frame: up to 2 years
Disease control rate (DCR) based on the RECIST 1.1 by principal investigator
up to 2 years
DOR
Time Frame: up to 2 years
Duration of response (DOR) based on the RECIST 1.1 by principal investigator
up to 2 years
CBR
Time Frame: up to 2 years
Clinical benefit rate (CBR) based on the RECIST 1.1 by independent review committee
up to 2 years
TTR
Time Frame: up to 2 years
Time to response (TTR) based on the RECIST 1.1 by independent review committee
up to 2 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety endpoint
Time Frame: up to 2 years
Serious adverse events (SAE), changes and abnormal findings in laboratory test, vital sign and physical examination.
up to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Caicun Zhou, MD,PhD, Shanghai Pulmonary Hospital, Shanghai, China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 28, 2021

Primary Completion (Actual)

February 13, 2023

Study Completion (Actual)

April 7, 2023

Study Registration Dates

First Submitted

July 16, 2021

First Submitted That Met QC Criteria

August 3, 2021

First Posted (Actual)

August 12, 2021

Study Record Updates

Last Update Posted (Actual)

April 25, 2023

Last Update Submitted That Met QC Criteria

April 23, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • KN046-302

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.